Due to an unfortunate series of events, the paper ‘Depression and Anxiety in Elderly Outpatients with Chronic Obstructive Pulmonary Disease: Prevalence and Validation of the BASDEC Screening Questionnaire’ by Yohannes AM, Baldwin RC and Connolly MJ (15(12): 1090–1096), intended for publication in JAGS, appeared in the December 2000 issue of the International Journal of Geriatric Psychiatry in place of this paper. The editor apologises for this mistake.
A feasibility study of antidepressant drug therapy in depressed elderly patients with chronic obstructive pulmonary disease†
Article first published online: 21 MAY 2001
Copyright © 2001 John Wiley & Sons, Ltd.
International Journal of Geriatric Psychiatry
Volume 16, Issue 5, pages 451–454, May 2001
How to Cite
Yohannes, A. M., Connolly, M. J. and Baldwin, R. C. (2001), A feasibility study of antidepressant drug therapy in depressed elderly patients with chronic obstructive pulmonary disease. Int. J. Geriat. Psychiatry, 16: 451–454. doi: 10.1002/gps.461
- Issue published online: 21 MAY 2001
- Article first published online: 21 MAY 2001
- Manuscript Accepted: 9 FEB 2000
- Manuscript Received: 28 OCT 1999
- old age;
- antidepressant treatment;
To examine the acceptability of fluoxetine in elderly depressed patients with chronic obstructive pulmonary disease (COPD).
A university teaching hospital.
Single-blinded (open) study. One hundred and thirty-seven outpatients (69 male) with symptomatic irreversible, moderate to severe COPD were recruited. Major depression was diagnosed using the Geriatric Mental State Schedule. Quality of life was assessed by the Breathing Problems Questionnaire, physical disability by the Manchester Respiratory Activities of Daily Living Questionnaire and severity of depression using the Montgomery Asberg Depression Rating Scale. Exclusion criteria were: use of oral steroids within 6 weeks, acute or chronic confusion, known cancer and known psychosis.
Fifty-seven patients (42%) (25 males) with a mean age of 72 years (range 60–89 years) were depressed. Fourteen (six male) agreed to undergo therapy with fluoxetine 20 mg/day for 6 months, while 36 (72%) refused antidepressant drug therapy. Only seven subjects completed the trial; of these, four (57%) responded to fluoxetine therapy. Five subjects withdrew because of side-effects. Twenty-two of those who refused treatment (61%) agreed to be interviewed, and of these 19 (86%) were still depressed.
Patient acceptance of fluoxetine was poor. The reasons for refusing treatment varied but were largely due to misapprehension by the patient. Untreated depression became chronic. Offering antidepressants to COPD patients with depression is not an effective strategy. Why this might be so is discussed. Copyright © 2001 John Wiley & Sons, Ltd